Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphomas

Shanghai Jiao Tong University

Status: Unknown

Conditions: Non-hodgkin Lymphoma,B Cell

Treatments: Drug: Lenalidomide

Study type: Observational

Funder types: Other

Identifiers

NCT04435743

LEN-NHL

Details and patient eligibility

About

Describe the treatment of B-cell non-Hodgkin lymphoma patients who receive lenalidomide single drug or lenalidomide combined with rituximab (with or without other drugs), and evaluate the efficacy and safety of lenalidomide single drug or lenalidomide combined with rituximab (with or without other drugs) in the real-world setting.

Full description

This is a multi-center prospective, observational real-world study, targeting patients with B-cell non-Hodgkin's lymphomas. This study is designed to evaluate the efficacy and safety of lenalidomide single drug or lenalidomide combined with rituximab (with or without other drugs) in the real-world setting.

This study will mainly focus on the following three cohorts:

Cohort 1: patients diagnosed with CD20-positive diffuse large B-cell lymphoma; Cohort 2: patients diagnosed with CD20-positive follicle lymphoma; Cohort 3: patients on maintenance treatment who have achieved complete remission or partial remission after induction therapy.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed as B-cell non-Hodgkin's lymphoma
• Voluntary participation in this study and the signing of an informed consent form
• The researchers assessed that the patient will benefit from the treatment of lenalidomide single drug or lenalidomide combined with rituximab (with or without other drugs)

Exclusion criteria

• Contradictions to any drug in the treatment regimen
• Pregnant or lactating women
• Patients who were not considered suitable for the study by the researchers

Trial design

1,000 participants in 3 patient groups

DLBCL

Description:

Treatment-naive or relapsed/refractory CD20+ diffuse large B-cell lymphoma patients who receive induction therapy containing lenalidomide.

Treatment:

Drug: Lenalidomide

FL/MCL/MZL

Description:

Treatment-naive or relapsed/refractory CD20+ follicular lymphoma, mantle cell lymphoma and marginal zone lymphoma patients who receive induction therapy containing lenalidomide.

Treatment:

Drug: Lenalidomide

Maintenance

Description:

B-cell non-Hodgkin lymphoma patients who achieve complete or partial remission after induction therapy and receive maintenance therapy containing lenalidomide.

Treatment:

Drug: Lenalidomide